BOLT BIOTHERAPEUTICS INC (BOLT)

US0977021049 - Common Stock

1.4  +0.18 (+14.75%)

After market: 1.34 -0.06 (-4.29%)

News Image
7 days ago - InvestorPlace

BOLT Stock Earnings: Bolt Biotherapeutics Beats EPS, Beats Revenue for Q4 2023

BOLT stock results show that Bolt Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

News Image
7 days ago - BusinessInsider

BOLT Stock Earnings: Bolt Biotherapeutics Beats EPS, Beats Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Bolt Biotherapeutics (NASDAQ:BOLT) just reported results for the fourth quarter...

News Image
8 days ago - Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

–   BDC-1001 (trastuzumab imbotolimod) Phase 2 studies in four HER2-positive tumor types advancing toward 2024 milestones–   BDC-3042 Phase 1 study...

News Image
a month ago - Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference

REDWOOD CITY, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel...

News Image
4 months ago - Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®

BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in Phase 2 development for HER2-positive breast, colorectal, endometrial, and...

News Image
5 months ago - Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

REDWOOD CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2023, and provided an update on the continued advancement of its clinical programs.

News Image
5 months ago - Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress

Updated safety data supports the selection of 20 mg/kg q2w as the recommended Phase 2 dose (RP2D)Improved efficacy with one partial response (PR) improving...

News Image
5 months ago - Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers

BDC-3042, a novel Dectin-2 agonistic antibody that stimulates the innate immune system, is being evaluated in a Phase 1/2 dose-escalation and expansion...

News Image
5 months ago - Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023

REDWOOD CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company pioneering...

News Image
6 months ago - Seeking Alpha

Bolt Bio stock spikes on FDA’s orphan status (NASDAQ:BOLT)

Bolt Biotherapeutics gains FDA's Orphan Drug Designation for BDC-1001, an immune-stimulating antibody conjugate for the treatment of gastric cancer. Read more here.

News Image
6 months ago - Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers

BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in Phase 2 development for HER2-positive breast, colorectal, endometrial, and...

News Image
7 months ago - Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042

REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing...

News Image
7 months ago - Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Participate in September Investor Conferences

REDWOOD CITY, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel...

News Image
8 months ago - Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

First patients dosed in the BDC-1001 Phase 2 programBDC-1001 Phase 1 data presented at ASCO 2023 demonstrated favorable safety profile and encouraging...

News Image
8 months ago - Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancer

BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in development for HER2-positive breast, colorectal, endometrial, and gastroesophageal...

News Image
8 months ago - Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023

REDWOOD CITY, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel...

News Image
10 months ago - Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual Meeting

Treatment with BDC-1001 at the recommended Phase 2 dose (RP2D) resulted in 29% objective response rate in evaluable patients with HER2-positive tumors, in...

News Image
a year ago - Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Comprehensive BDC-1001 clinical safety and efficacy data as a single agent and in combination with nivolumab, including RP2D, to be presented at ASCO...

News Image
a year ago - Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual Meeting

Comprehensive Phase 1 data at ASCO support initiation of two Phase 2 trials...